Effectiveness and safety outcomes for rt-PA and UK
| Outcome | rt-PA n/N (%) | UK n/N (%) | Unadjusted OR or mean difference (95% CI) | P value | Adjusted OR or mean difference (95% CI)* | P value |
| mRS scores 0 to 1 at 90 days | 1902/2666 (71.3) | 795/1144 (69.5) | 1.09 (0.94 to 1.27) | 0.250 | 1.15 (0.98 to 1.35) | 0.078 |
| mRS scores 0 to 2 at 90 days | 2174/2666 (81.5) | 910/1144 (79.5) | 1.14 (0.96 to 1.35) | 0.150 | 1.22 (1.01 to 1.46) | 0.036 |
| mRS distribution at 90 days | 0.369 | 0.140 | ||||
| 0 | 1043/2666 (39.1) | 409/1144 (35.8) | ||||
| 1 | 859/2666 (32.2) | 386/1144 (33.7) | ||||
| 2 | 272/2666 (10.2) | 115/1144 (10.1) | ||||
| 3 | 175/2666 (6.6) | 94/1144 (8.2) | ||||
| 4 | 118/2666 (4.4) | 50/1144 (4.4) | ||||
| 5 | 77/2666 (2.9) | 32/1144 (2.8) | ||||
| 6 | 122/2666 (4.6) | 58/1144 (5.1) | ||||
| ΔNIHSS score to 24 hours† | 2.4±5.1 | 2.0±4.4 | 0.20 (−0.21 to 0.61) | 0.334 | 0.23 (−0.10 to 0.57) | 0.173 |
| ΔNIHSS score to 14 days† | 3.7±6.1 | 3.1±5.5 | 0.14 (−0.25 to 0.53) | 0.470 | 0.28 (−0.14 to 0.70) | 0.194 |
| sICH at 36 hours | 30/2666 (1.1) | 16/1144 (1.4) | 0.80 (0.44 to 1.48) | 0.479 | 0.69 (0.35 to 1.35) | 0.281 |
| Other bleeding events | 30/2666 (1.1) | 8/1144 (0.7) | 1.62 (0.74 to 3.54) | 0.230 | 1.48 (0.66 to 3.29) | 0.341 |
| Recurrent stroke at 90 days | 36/2557 (1.4) | 28/1097 (2.6) | 0.55 (0.33 to 0.90) | 0.016 | 0.57 (0.34 to 0.94) | 0.028 |
| All-cause mortality at 90 days | 122/2666 (4.6) | 58/1144 (5.1) | 0.90 (0.65 to 1.24) | 0.510 | 0.76 (0.52 to 1.12) | 0.164 |
*Propensity scores adjustment for all baseline variables in the model.
†From baseline.
mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen activator; sICH, symptomatic intracerebral haemorrhage; UK, urokinase.